Enzo Therapeutics, Inc. v. Yeda Research & Development Co. of the Weizmann Institute of Science

467 F. Supp. 2d 579, 2006 U.S. Dist. LEXIS 88497
CourtDistrict Court, E.D. Virginia
DecidedDecember 6, 2006
DocketCivil Action 2:06cv377
StatusPublished
Cited by1 cases

This text of 467 F. Supp. 2d 579 (Enzo Therapeutics, Inc. v. Yeda Research & Development Co. of the Weizmann Institute of Science) is published on Counsel Stack Legal Research, covering District Court, E.D. Virginia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Enzo Therapeutics, Inc. v. Yeda Research & Development Co. of the Weizmann Institute of Science, 467 F. Supp. 2d 579, 2006 U.S. Dist. LEXIS 88497 (E.D. Va. 2006).

Opinion

OPINION AND ORDER

DOUMAR, District Judge.

Presently before the Court is a motion by Defendant Jon W. Dudas, in his capacity as Director of the United States Patent and Trademark Office (the “Director”), to dismiss claims filed against him on July 3, 2006, by Plaintiff Enzo Therapeutics, Inc. (“Enzo”). The underlying lawsuit, filed pursuant to 35 U.S.C. § 146, asserts four claims against the Director and Yeda Research and Development Company (“Teda”) that emerged from an interference proceeding (the “Interference”) conducted by the Board of Patent Appeals and Interference (the “Board”). Count I alleges that the Board abused its discretion by deciding a petition for which it lacks jurisdiction, and that, consequently, Enzo is entitled to have the Interference decision withdrawn and the question of priority reexamined by this Court. Count II alleges that the. Board’s Interference decision and factual determinations are unsupported by substantial evidence, and that new findings on the question of priority are warranted on appeal. Count III alleges the Director violated the Administrative Procedure Act, 5 U.S.C. § 706, by acting with unreasonable delay in failing to resolve a petition filed by Enzo on April 12, 2006, appealing the Board’s Interference decision. Finally, Count IV prays for a writ of mandamus to compel the Director to decide the same April 12, 2006, petition. The Director seeks dismissal of Enzo’s Complaint for lack of subject matter jurisdiction, pursuant to Federal Rule of Civil Procedure 12(b)(1), and for failure to state a claim upon which relief can be granted, pursuant to Rule 12(b)(6).

For the reasons stated herein, the Court GRANTS the motion to dismiss Counts I and II as to the Director, and GRANTS the motion to dismiss Counts III and IV in their entirety.

I. FACTUAL AND PROCEDURAL BACKGROUND

A. Factual Allegations

Like many claims that arise out of federal administrative hearings, the facts in this case are grounded in a labyrinth of administrative procedure. The United States Patent and Trademark Office (“USPTO”) primarily conducts two types of patent proceedings. The majority are ex parte examinations of patent applications involving a single applicant, and conducted by a patent examiner who interfaces with the applicant during the application process. An applicant dissatisfied with the patent examiner’s decision may appeal to the Board. If the applicant remains dissatisfied following the Board’s review, another appeal may be made by filing a civil action in the United States Court of Appeals for the Federal Circuit, 35 U.S.C. § 145 (2006), or in the United States District Court for the District of Columbia, 35 U.S.C. § 145 (2006). In such judicial actions, the Director is a necessary party to defend the Board’s decision in court. Id.

The second' type of patent proceeding occurs when the USPTO believes two or more parties have invented the same in *582 vention at or about the same time. Such an inter partes proceeding is heard before the Board and intended to resolve the question of priority. Because patents are typically issued on the basis of who created the patent first in time, the resolution of such a hearing is of critical importance to the parties. See Alexander Milburn Co. v. Davis-Bournonville Co., 270 U.S. 390, 400, 46 S.Ct. 324, 325, 70 L.Ed. 651 (1926) (“[0]ne really must be the first inventor in order to be entitled to a patent.”). A dissatisfied party to an interference may either appeal the Board’s decision to the Court of Appeals for the Federal Circuit, 35 U.S.C. § 141 (2006), or file a civil action in any federal district court in which venue is proper, 35 U.S.C. § 146 (2006).

The events leading to the Interference, and this § 146 appeal, began on April 17, 1981, when Enzo filed U.S. Patent Application Serial No. 06/255,215 (“the '215 application”) naming Pravinkumer B. Sehgal as the inventor. 1 Over one year thereafter, on September 28, 1982, Yeda filed U.S. Patent Application Serial No. 06/425,933 (“the '933 application”), naming Michel Revel, et al., as inventors. On January 27, 1984, the USPTO issued a Final Office Action rejecting the pending claims of Enzo’s '215 application, and granted Enzo three months to respond. Enzo admittedly failed to respond to the Board during this time, and the USPTO abandoned Enzo’s '215 application on April 30, 1984. Nearly three months after such abandonment, on July 27, 1984, Enzo filed a continuation application, U.S. Patent Application Serial No. 06/634,998 (“the '998 application”). For a number of years thereafter, Enzo filed the following additional applications to the USPTO to create a “chain” of patent applications: U.S. Patent Application Serial No. 07/191,517 on May 6, 1988; 07/869,073 on April 10, 1992; 08/300,872 on June 16, 1994; and, finally, 08/479,996 (“the '996 application”) on June 7, 1995. Notwithstanding this chain of applications, the Board granted Yeda’s '933 application on November 25, 2005, and issued to Yeda U.S. Patent No. 5,468,609 (“the '609 patent”).

By Enzo’s request, the Board declared the Interference between Enzo’s '996 application and Yeda’s '609 patent on March 15, 2005, in which Enzo claimed a priority date of April 17, 1981, via the series of applications it had filed with the Board culminating in the '996 application of June 7, 1995. On April 29, 2005, Yeda moved for the Board to deny Enzo’s '996 application the benefit of the '215 application for lack of codependency between the two filings. Yeda contended that Enzo’s failure to respond to the USPTO’s Final Office Action in 1984 caused the '215 application to be abandoned on April 30, 1984, thereby breaking the supposed chain of continuity. As such, the appropriate date establishing Enzo’s priority should have been the date of the initial application after the 1984 abandonment, the '998 application, filed on July 27, 1984. The Board accepted Yeda’s argument and redeclared the Interference on May 18, 2005, without according Enzo the benefit of the '215 application filing date.

On July 1, 2005, Enzo filed a motion pursuant to 37 C.F.R. § 41.121(a)(1) ask *583 ing the Board to revive the '215 application and to accord Enzo the benefit of the April 17,1981, filing date on the basis that abandonment in 1984 was unintentional (“Motion for Benefit”). The Motion for Benefit contained an additional petition, styled Petition under 37 C.F.R.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Enzo Therapeutics, Inc. v. Yeda Research & Development Co.
477 F. Supp. 2d 699 (E.D. Virginia, 2007)

Cite This Page — Counsel Stack

Bluebook (online)
467 F. Supp. 2d 579, 2006 U.S. Dist. LEXIS 88497, Counsel Stack Legal Research, https://law.counselstack.com/opinion/enzo-therapeutics-inc-v-yeda-research-development-co-of-the-weizmann-vaed-2006.